This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Jill and Carlo discuss the pending approval for Pfizer's vaccine for kids, the state of anti-Semitism three years after Tree of Life, potential criminal charges in the 'Rust' prop gun shooting and more.
Amalgamated Bank is the first U.S. bank to publish science-based targets to reach net-zero greenhouse gas emissions by 2045. The bank says it will reach this goal through how it engages with customers and how it finances projects. Amalgamated Bank Chief Sustainability Officer Ivan Frishberg joined Cheddar Climate to provide more details about the bank's ambitious climate goals.
COP26 been dealt a blow as Chinese President Xi Jinping and Russian President Vladimir Putin, whose countries are responsible for a third of the world's annual greenhouse gas emissions, will not be in attendance. Bertrand Piccard, Chairman and Founder of the Solar Impulse Foundation, joins Cheddar Climate, where he discusses what he expects to see when the summit commences in Glasgow.
John Nosta, WHO Technology Expert, joins Cheddar News to discuss evolving technology in the healthcare industry and the role 5G is playing in advancing healthcare delivery.
According to the latest report from the UN, several countries around the world are "nowhere near" towards their goal of limiting gas emissions. This report comes ahead of the COP26 which is slated to take place in the month of November in Scotland. Senior Advisor at CDP Paula Diperna, joined Cheddar to discuss what the report highlights and what this tells us about the future plans of the Paris Climate Agreement.
Powerful weather systems over California have caused record amounts of rainfall in the state, including over wildfire-scorched lands since triggering massive landslides.
The FDA meets today on whether or not vaccines for children ages 5-11 can potentially become available to the public. Cheddar News was joined by Dr. Richard Besser, President and CEO of the Robert Wood Johnson Foundation and former Acting Director of the CDC to discuss what could come next for these vaccines.
Dan DePodwin, Director of Forecasting Operations at AccuWeather, joined Wake Up With Cheddar to talk about the extreme weather across the country, including damaging rains in the drought-stricken western U.S. and an incoming Nor'easter that's likely to cause flooding and power outages along the Atlantic coast.
Jill and Carlo cover the news out of Facebook's latest earnings, Tesla's monumental day, Dave Chappelle addresses controversy and the tragedy of the climate emergency.
The UN's World Meteorological Organization reported that carbon dioxide in the atmosphere hit record levels in 2020, despite coronavirus-related lockdowns. With the COP26 international meeting on climate change less than a week away, Risk and behavioral scientist Dr. Sweta Chakraborty joined Cheddar to break down the "code red for humanity" the report represents and what actual commitments must be made to prevent significant global temperature increases.
